ABSTRACT

Introduction: As a result of progress in medical care, a huge number of medical devices are used in the treatment of human diseases. In turn, biofilm-related infection has become a growing threat due to the tolerance of biofilms to antimicrobials, a problem magnified by the development of antimicrobial resistance worldwide. As a result, successful treatment of biofilm-disease using only antimicrobials is problematic.

Areas covered: We summarize some alternative approaches to classic antimicrobials for the treatment of biofilm disease. This review is not intended to be exhaustive but to give a clinical picture of alternatives to antimicrobial agents to manage biofilm disease. We highlight those strategies that may be closer to application in clinical practice.

Expert opinion: There are a number of outstanding challenges in the development of novel antibiofilm therapies. Screening for effective antibiofilm compounds requires models relevant to all clinical scenarios. Although in vitro research of anti-biofilm strategies has progressed significantly over the past decade, there is a lack of in vivo research. In addition, the complexity of biofilm biology makes it difficult to develop a compound that is likely to provide the single ‘magic bullet’. The multifaceted nature of biofilms imposes the need for multi-targeted or combinatorial therapies.

摘要

简介：随着医疗保健的进步，大量的医疗器械被用于治疗人类疾病。反过来，由于生物膜对抗菌剂的耐受性，与生物膜相关的感染已成为日益严重的威胁，这一问题随着全球抗菌素耐药性的发展而扩大。因此，仅使用抗微生物剂成功治疗生物膜疾病是有问题的。

涵盖的领域：我们总结了一些用于治疗生物膜疾病的经典抗菌药物的替代方法。这篇综述并非详尽无遗，而是给出了治疗生物膜疾病的抗菌药物替代品的临床图片。我们强调那些可能更接近临床实践应用的策略。

专家意见：新型抗生物膜疗法的开发存在许多突出的挑战。筛选有效的抗生物膜化合物需要与所有临床情况相关的模型。尽管抗生物膜策略的体外研究在过去十年中取得了显着进展，但缺乏体内研究。此外，生物膜生物学的复杂性使得开发一种可能提供单一“灵丹妙药”的化合物变得困难。生物膜的多面性要求需要多靶点或组合疗法。